These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26586838)

  • 1. Morphometric changes correlate with poor psychological outcomes in patients with acromegaly.
    Imran SA; Tiemensma J; Kaiser SM; Vallis M; Doucette S; Abidi E; Yip CE; De Tugwell B; Siddiqi F; Clarke DB
    Eur J Endocrinol; 2016 Jan; 174(1):41-50. PubMed ID: 26586838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance.
    Matta MP; Couture E; Cazals L; Vezzosi D; Bennet A; Caron P
    Eur J Endocrinol; 2008 Mar; 158(3):305-10. PubMed ID: 18299462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
    Gondim JA; Almeida JP; de Albuquerque LA; Gomes E; Schops M; Ferraz T
    Neurosurg Focus; 2010 Oct; 29(4):E7. PubMed ID: 20887132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
    Schwyzer L; Starke RM; Jane JA; Oldfield EH
    J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide lar affects the volume of pituitary adenoma in acromegalic patients.
    Bałdys-Waligórska A; Krzentowska-Korek A; Gołkowski F; Sokołowski G; Hubalewska-Dydejczyk A
    Exp Clin Endocrinol Diabetes; 2011 May; 119(5):295-9. PubMed ID: 21264808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly.
    Postma MR; Netea-Maier RT; van den Berg G; Homan J; Sluiter WJ; Wagenmakers MA; van den Bergh AC; Wolffenbuttel BH; Hermus AR; van Beek AP
    Eur J Endocrinol; 2012 Apr; 166(4):585-92. PubMed ID: 22250074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term facial changes and clinical correlations in patients with treated acromegaly: a cohort study.
    Du F; Chen Q; Wang X; Guo X; Wang Z; Gao L; Long X; Xing B
    Eur J Endocrinol; 2021 Feb; 184(2):231-241. PubMed ID: 33112282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent self-consciousness about facial appearance, measured with the Derriford appearance scale 59, in patients after long-term biochemical remission of acromegaly.
    Roerink SH; Wagenmakers MA; Wessels JF; Sterenborg RB; Smit JW; Hermus AR; Netea-Maier RT
    Pituitary; 2015 Jun; 18(3):366-75. PubMed ID: 24965695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit.
    Roug S; Rasmussen AK; Juhler M; Kosteljanetz M; Poulsgaard L; Heebøll H; Roed H; Feldt-Rasmussen U
    Eur J Endocrinol; 2010 Apr; 162(4):685-94. PubMed ID: 20133445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
    Arosio M; Garrone S; Bruzzi P; Faglia G; Minuto F; Barreca A
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1091-8. PubMed ID: 11238491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The quality of life and psychological, social and cognitive functioning of patients with acromegaly.
    Szcześniak D; Jawiarczyk-Przybyłowska A; Rymaszewska J
    Adv Clin Exp Med; 2015; 24(1):167-72. PubMed ID: 25923102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
    Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body Image Perception in Acromegaly Is Not Associated with Objective Acromegalic Changes but Depends on Depressive Symptoms.
    Dimopoulou C; Leistner SM; Ising M; Schneider HJ; Schopohl J; Rutz S; Kosilek R; Frohner R; Stalla GK; Sievers C
    Neuroendocrinology; 2017; 105(2):115-122. PubMed ID: 27453978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Craniometric changes in patients with acromegaly from a surgical perspective.
    Ebner FH; Kürschner V; Dietz K; Bültmann E; Nägele T; Honegger J
    Neurosurg Focus; 2010 Oct; 29(4):E3. PubMed ID: 20887128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and functional changes of carotid wall properties in patients with acromegaly are not restored after 1 year of GH/IGF1 normalization.
    Găloiu S; Jurcuţ R; Vlădaia A; Florian A; Purice M; Popescu BA; Ginghină C; Coculescu M
    Exp Clin Endocrinol Diabetes; 2012 Apr; 120(4):238-43. PubMed ID: 22426806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas.
    Campbell PG; Kenning E; Andrews DW; Yadla S; Rosen M; Evans JJ
    Neurosurg Focus; 2010 Oct; 29(4):E5. PubMed ID: 20887130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
    Bastemir M; Akin F; Yaylali GF
    Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study.
    Kyriakakis N; Lynch J; Gilbey SG; Webb SM; Murray RD
    Clin Endocrinol (Oxf); 2017 Jun; 86(6):806-815. PubMed ID: 28316090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.